Citicoline supplementation may significantly slow glaucoma progression

An Italian study found 500 mg dose of Kyowa’s Citicoline may improve eye health

Citicoline is a brain health nutrient, which is now believed to significantly slow the progression of visual acuity loss due to glaucoma.

Researchers at the Sao Paolo Hospital Eye Clinic at the University of Milan followed 41 patients with progressing glaucoma, a disease that damages the optic nerve and can lead to vision problems and blindness.

The study targeted individuals with primary open-angle glaucoma (POAG), which is associated with increased eye pressure and a resulting loss of the field of vision.

Participants were given an oral solution containing 500 mg of citicoline (Kyowa). The mean rate of progression dropped dramatically compared to the 2 years prior to the study.

The study also found there was a statistically significant decrease in intraocular pressure. It is not conclusive that citicoline alone is responsible for the results; however supplementation with citicoline may be beneficial in overall brain and eye health.

Citicoline is a nutrient that helps the brain generate electrical impulses, care for healthy brain cells, and protect neurons from free radical damage. It supports memory and cognitive function, while aiding in the synthesis and maintenance of cell membranes.

Citicoline is a substance found in every cell of the body and it is vital to brain health and eye health. Citicoline is broken down during intestinal absorption and after passing through the blood/brain barrier, is reconstituted in the brain as citicoline.

These statements have not been evaluated by the Food and Drug Administration or the European Commission. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

This study was published online in Ophthalmologica, 219-226 (2013)

Companies